🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchAnyone else refreshing ClinicalTrials.gov every morning or just me Page 3

Anyone else refreshing ClinicalTrials.gov every morning or just me

TrialNerd_Beth Thu, Apr 30, 2026 at 8:30 AM 22 replies 944 viewsPage 3 of 5
DanielChem_CHI
Senior Member
1,234
5,678
Mar 2024
Chicago, IL
May 1, 2026 at 3:20 PM#11
VendorMark said:
Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to: Point estimate (HR/RR/OR) —…

Agreed on the substance. I would put less weight on the timescale, because two months of anything is not enough to distinguish a trend from a wobble.

Last edited: May 1, 2026 at 5:20 PM
10 10fiona_VT, denise_HTX, raj_cambridge and 7 others
Reply Quote Save Share Report
MikeNYC_runner
Member
378
1,678
Jul 2024
New York, NY
May 2, 2026 at 8:41 AM#12
BethLabQueen said:
LipidDoc_ATL said: ...regarding the trial evidence...

Thank you — that is the clearest version of this I have read, and I have read a lot of them. Sending this to two other people who asked me the same thing last week.

9 9HealthEcon_DC, PedsEndoPhilly, SleepDoc_PDX and 6 others
Reply Quote Save Share Report
JennaRN
Senior Member
1,987
8,923
Mar 2024
Colorado
Online
May 3, 2026 at 2:03 AM#13
VendorMark said:
Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to: Point estimate (HR/RR/OR) —…

This is where I part company with the consensus forming above. Pushing back on the anecdote-stacking. Twenty people reporting the same thing is twenty samples from the same self-selected pool, not twenty independent confirmations.

8 8BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 5 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
raj_cambridge
Member
489
2,123
Jun 2024
Cambridge, MA
May 3, 2026 at 7:25 PM#14

The figures, for anyone assembling their own picture. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

7 7PharmHunterJen, TomTeleRx, DoseLogDan and 4 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
May 4, 2026 at 12:48 PM#15

Moderator note: a couple of off-topic posts removed.

6 6PurityPaulOR, MaxMetOK, MounjBrad and 3 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register